Medreich plant makes improvements but France says it doesn't matter

Bangalore
Bangalore

After running afoul of French regulators in 2014 for dozens of violations at a plant in Andhra Pradesh, Indian generics maker Medreich put together a comprehensive action plan to bring it back into compliance. France’s ANSM recently acknowledged that it appears Medreich has met its goals, but it also said it won’t bother going back for the reinspection that could lead to it reinstate Medreich’s certificate of compliance.

Medreich’s problems at the plant that manufactures B-lactam antibiotics were first noted during an inspection in 2013. When the regulator returned in 2014, inspectors cited 58 deficiencies, including one concerning data being faked that was classified as critical. Another 29 were classified as major and included a variety of problems related to cross-contamination, inadequate visual inspections and a "poor level of quality management."

Medreich pulled its products from the market and set about getting the plant in order. The ANSM acknowledged in a report posted by the European Medicines Agency (EMA) this week that it has received and reviewed the action plan from Medreich and that it addresses the issues raised during the inspection.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

“However, due to the absence of any national product on the French market and the absence of any pending application involving this site, ANSM will not perform a follow-up inspection of this site to ensure the effective implementation of this action plan.” As a result, it said the “statement of non-compliance previously issued is maintained and the site should not be named on any marketing authorisations whilst this statement remains in place.”

Medreich is owned by Japan's Meiji Holdings, a small conglomerate that manufactures pharmaceuticals as well as candy and dairy products, which bought the Bangalore-based generics maker in 2014 for about $290 million. According to the Medreich website, the company has 8 manufacturing facilities and 2,000 employees worldwide.

- access the ANSM report here  

Related Articles:
France and Italy ban products from Indian companies
Japan's Meiji snaps up Indian CMO Medreich for $290M

Suggested Articles

Three Samsung execs face up to two years in jail for their roles in destroying data and documents at under-fire affiliate Samsung BioLogics.

The FDA has slapped a U.S. drug repackager, saying in a warning letter that its storage processes and equipment cleaning are not up to expectations.

Higher operating costs were behind a 17% slide in pretax profits last year at Allergan’s Mayo, Ireland, facility that produces Botox.